SUBSTIPHARM Email Format

Pharmaceutical ManufacturingÎle-de-France, France51-200 Employees

Substipharm is a privately held pharmaceutical group headquartered in Paris, France, with a workforce of 51–200 employees. The company develops, supplies and commercializes pharmaceuticals in more than 90 countries, maintaining a portfolio of over 90 molecules and a development pipeline with more than 50 ongoing projects. Its product lineup includes mature brands, generics, OTC medicines, difficult-to-develop medicines, value-added presentations, and biological products including vaccines. Substipharm has engaged in international vaccine collaborations, notably for the Japanese Encephalitis vaccine IMOJEV, including a 2026 arrangement with Emergent BioSolutions to support manufacturing and exclusive U.S. distribution, and a 2024 partnership with Zuellig Pharma to expand access in Asia, as well as earlier asset transfers such as hydrocortisone rights acquired in 2022 from Biocodex. The company is located at 24 Rue Erlanger, Paris, Île-de-France 75016, France.

Get verified SUBSTIPHARM emails free

Company overview Employee directory